Accessibility links Skip to main content

Achieving Inspection Readiness in Pharma

Having undergone 4 inspections in the last 2 years and supported clients for numerous mock inspections MIAS has gained valuable knowledge and experience in this area to share.

Contact us

Fill out the form and we will contact you shortly.

Naam
Privacy Policy 
Continue reading

Why be Inspection Ready?

In the lifecycle of a pharmaceutical company an inspection from a regulatory body is a certainty. Whether it be for the initial approval of your licence or ongoing approval they are going to happen. With the FDA recently expanding its unannounced inspection program a site can no longer rely on having 6 weeks’ notice to prepare. The inspectors can turn up at your gates on Monday morning and you have to be ready to host.

inspection readiness process

Pre inspection preparation:

There are some key elements to getting ready for an inspection amongst them are arranging who is responsible for what, starting with the backroom team and scribes. Having experienced personnel supporting in the backroom can be a great support for the front room team with pre-screening of documents. Where possible utilise technology such as setting up an inspection teams chat, with clear rules on communication and formatting and of requests e.g. “inspector requests SOP on deviations” rather than “can someone please get the deviation SOP.”

Doing exercises such as mock inspections with either external parties or using members of the internal team can be a great way to get the team into the headspace of how to handle the pressure of an inspection. Using a “hat-on/hat off” technique during these sessions permits immediate feedback and coaching to members of the team likely to be sitting opposite an inspector(s).

Executing the mock inspections also help to identify potential “Achilles heels” and allow you time to either correct them or prepare a storyboard to aid in the explanation of a complex process, deviation or problem.

Preparation of PQS:

In advance of the inspection there are usually requests from the inspector(s) for documents this may include those listed below:

Key Documents

SOP indexList of GMP computer systems and software
List of Product Quality Reviews (PQRs) completed in the period since the last inspectionList of Technical Agreements
List of deviations/non-conformances/quality investigations raised in the period since the last inspectionList of contract manufacturers and contract laboratories (if applicable)
List of customer complaints raised since the last inspectionList of any other outsourced GMP services
List of laboratory investigations raised since the last inspection3rd Party Audit and Self Inspection program
List of change controls raised since the last inspectionTraining Programme
List of rejected batches (if any) since the last inspectionSupply Chain Maps
List of reworked batches (if any) since the last inspectionValidation Master Plan
List of reprocessed batches (if any) since the last inspectionSite Master File
List of product recalls (if any) since the last inspectionContamination Control Strategy
List of Released Batches since the last inspection 

 

Suggested Actions

• Perform sanity checks on these documents and confirm they are complete, up to date, no gaps are present and any CAPAs are closed or on track
• Review any critical and major changes and investigations will help to ensure familiarity.
• For paper based PQS’s verify that you can quickly retrieve any records

Preparation of Premises

Key documents related to your facilities and equipment to have available can include:

Key Documents

  • HVAC System Site Drawings and Validation Reports​
  • Water System Site Drawings and Validation Reports​
  • Clean Steam Site Drawings and Validation Reports​
  • Compressed Air Site Drawings and Validation Reports
  • List of Critical production equipment​
  • List of Critical laboratory equipment​
  • Cleaning Validation program​
  • Validation Master Plan

Suggested Actions

• Performing regular walkthroughs of manufacturing areas with people familiar and unfamiliar with the area. This can help to point out or ask questions about things that people familiar with the area may miss.
• Have a 5S approach to all areas and confirm that all equipment are fully qualified and log books are up to date

Preparation of Personnel

With regards to the personnel at your site, key documents would include:

Key Documents

  • Training Records
  • Evidence of audit qualifications
  • Continued Professional Development (CPD) for QPs
  • Annual GxP training
  • Annual Training Plan

Suggested Actions

• Personnel to review their training records for completeness
• Confirm evidence of annual GxP training and CPD for QPs is available
• Ensure awareness of inspection occurrence and inspection behaviours

In summary, the more time and effort put into preparing for an inspection the easier it can be. It comes down to the old saying “fail to prepare, prepare to fail”. Ensuring that the team know their processes, are well drilled and are open and honest with the inspector can lead to a smoother inspection process.

Your partner in quality, safety, and compliance

The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.

Related services

QP Services

Clinical QP Services

Related articles

07 Apr 2026

MIAS Pharma will be attending the BIO International Convention in San Diego, USA

MIAS Pharma is excited to attend the BIO International convention in San Diego, California, from June 22nd – 25th 2026. Visit us at booth #4052, we’ll be happy to connect.

01 Apr 2026

Let’s Meet at SNMMI Annual meeting 2026 LA

MIAS Pharma is excited to attend the SNMMI annual meeting in Los Angeles, California, from May 30th – June 2nd 2026. Visit us at booth #1363, we’ll be happy to connect.

20 Mar 2026

Labelling & Packaging: A Core MAH Responsibility

Marketing Authorisation Holders (MAHs) carry primary responsibility for the accuracy, control, and lifecycle management of labelling and packaging across all markets where a product is placed on the EU/EEA market. This obligation extends beyond artwork creation to encompass regulatory approval, change control, supply chain implementation, and post‑market vigilance for labelling‑related quality defects and recalls.

13 Mar 2026

Getting ready for product launch with serialisation

As your medicinal product moves from the clinical space into commercial launch territory, one crucial question looms large:

06 Mar 2026

MAHs: Are Your GMP–GVP Interfaces Aligned?

Calling all Marketing Authorisation Holders (MAHs) are you set up for success? Have you confirmed whether your five‑year renewal is required? Is this critical information visible and accessible to your QPs and QPPVs?

27 Feb 2026

MIAS Pharma: End to End MAH services for Virtual and Rare Disease Companies

For small and virtual companies, especially those developing rare disease medicines, the requirements of acting as a Marketing Authorisation Holder (MAH) in the EU can feel overwhelming. EU legislation places the MAH at the centre of responsibility for the quality, safety and efficacy of the product throughout its lifecycle, regardless of how many activities are outsourced. MIAS Pharma is designed to be your one integrated partner in Europe: an established presence with the expertise, infrastructure and network to assume day‑to‑day MAH obligations on your behalf while you focus on science, patients and portfolio strategy.

28 Jan 2026

Navigating Evolving EU Marketing Authorisation: Are You Ready for Tomorrow’s Compliance?

As the European pharmaceutical landscape transforms, Marketing Authorisation Holders (MAHs) now face a broader – and more demanding – array of duties that stretch far beyond initial product approval. The new compliance reality encompasses critical operational areas like shortage reporting, environmental risk management, end-to-end product data maintenance, supply chain resilience, and more. These obligations often overlap with, yet are legally distinct from, manufacturing and wholesale authorisations – presenting new blind spots and risks for the unprepared.